(link). Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real Time Price. Please speak with your recruiter for more information. There is a pregnancy exposure registry that monitors the outcomes of females who take REVLIMID during pregnancy, or if their male partner takes REVLIMID and they are exposed during pregnancy. The company was founded in 1887 and is based in New York, New York. This website uses cookies to provide website functionality. (, In November, the company presented new data from across its cardiovascular portfolio (, Phase 2 AXIOMATIC-TKR trial that showed milvexian reduced the risk of postoperative venous thromboembolism in a dose dependent manner without increasing the risk of bleeding compared with enoxaparin in patients undergoing total knee replacement surgery. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. endobj The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. )yJP There are regular US holidays with 4 floating holiday/personal days. Gross margin increased from 73.7% to 80.3% in the quarter primarily due to an impairment charge related to marketed product rights in the same period a year ago and lower unwinding of inventory purchase price accounting adjustments. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibbs business nor reflect Bristol Myers Squibbs underlying business performance. Engage with instructors and fellow students for half-day or up to three-day programs in a virtual or classroom setting. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. startxref This culture of inclusion encourages everyone to pursue innovative ideas, develop leadership capabilities and gain valuable, diverse experiences to shape exciting careers. Total Rewards may differ based on country; the benefits described on this site are specific to those in the U.S. Top 50%. THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. Turning Point Therapeutics Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer. These statements are likely to relate to, among other things, the companys ability to execute successfully its strategic plans, including its business development strategy and capital allocation strategy, planned product launches and updates, expectations relating to its pipeline and in relation to its ability to realize the projected benefits of the Celgene acquisition and the MyoKardia acquisition, the full extent of the impact of the COVID-19 pandemic on the companys operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about the companys ability to retain patent exclusivity of certain products, and the impact and the result of governmental investigations. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. International revenues increased 4% to $4.5 billion in the quarter. Investors. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Israel holiday schedule. 0000008533 00000 n Materials on this website may contain information about the Companys future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. Add to iCalendar. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and the subsequent merger, (ii) the number of shares of the Turning Point Therapeutics common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for Turning Point Therapeutics, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. Upcoming events. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. The 2022 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in seven European countries from 2-19th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and ET on February 4 through 11:30 a.m. #BMSCareers. Job security always hanging over your head. trailer Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. In a scientific, business or supporting function, theres no better place to do some of the most interesting and meaningful work of your career. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. This led to the automatic termination of the CVR agreement Jan. 1,2021 rendering the CVRs as ineligible for payment under the agreement. Learn about Bristol Myers Squibb Paid Holidays, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. This was driven by its aforementioned revenue growth, a 330-basis-point. Both GAAP and non-GAAP guidance assume current exchange rates. The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. Additional Information about the Tender Offer and Where to Find it. No additional data or studies have been requested. Month List Download. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram . Bristol-Myers Squibb has 9 holidays and 4 personal/floating holidays. 0000011122 00000 n Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. Returns Potential A 15% price target upside from sell-side analysts. BMS Benefits and Work Life. Warnings Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug. #BMSCareers. Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. Working among other smart, creative and talented colleagues, youll find support and uncommon opportunities to learn, grow and lead. Our mission to enhance the lives of patients requires an investment in a strong learning culture. INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. U.S. revenues increased 11% to $7.5 billion in the quarter. Bristol-Myers Squibb's report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared TipRanks Team May 19, 2021. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company's pipeline that further progressed the company's portfolio renewal. A discussion of the non-GAAP financial measures is included under the Use of Non-GAAP Financial Information section. Bristol-Myers Squibb BMY | stock $69.02 0.09% $147 B 3.31% $2.28 - Ratings - BMY Dividend Safety A+ 16 years of consecutive dividend increase. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Jun 13, 2021 9:01AM EDT. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. No cons. We routinely post important information for investors on our website, BMS.com, in the Investors section. Forward-looking statements are based on current expectations and projections about the companys future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the companys control and could cause the companys future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. (This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion) (Reuters) - Drugmaker Bristol Myers (NYSE: BMY) Squibb Feb 07, 2021, 01:50 AM. Bristol-Myers June 17 (Reuters) - Bristol-Myers Squibb Co BMY.N and Eisai Co said on Thursday they had entered into an A Reminder to Patients Applying to the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) If you are applying to BMSPAF for the first time or for continued assistance, your application may be processed more quickly if you include proof of your household income from a Federal Tax Return or other sources of income documentation including: [Updated: 3/26/2021] BMY Stock Looks Undervalued At $63. The case is UMB Bank NA v Bristol-Myers Squibb (NYSE: BMY) Co et al, U.S. District Court, Southern District of New York, No. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. Events and Presentations. No forward-looking statement can be guaranteed. Learn about our safety approach to COVID-19 >. Bristol ups aid. Case Timeline November 12, 2021 PRESS RELEASE: FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement January 13, 2020 File Complaint (112.81 KB) File Stocks gain as Bostic backs quarter-point hike; Hewlett Packard Enterprise lifts annual guidance after Q1 results beat estimates; Fed wrestles whether recent data a 'blip' or a warning on inflation Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. 0000006923 00000 n Ensure day-day logistics operations are meet. In celebration of the five generations that make up our workforce, we offer benefits to help you through every stage and milestone of life. Best place for vacation and time off, BMS incentivize family time. I'm a new hire. I'm ready to enroll! xref On-site services depending on location, such as Federal Credit Union, dry cleaning, automobile detailing and massage therapy. Available to US-based employeesChange location, Comparable to many others in the same league. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. With support and coaching from your colleagues, youre encouraged to take on stretch assignments that maximize your learning experience. Research and development expenses decreased 30% to $2.6 billion in the quarter. The FDA has accepted the NDA and the EMA has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. Diversifier. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. A dds details on agreement, background. An effective tax rate of approximately 24% for GAAP and approximately 16.5% for non-GAAP. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Here we feature several BMS colleagues sharing their views on the subject from their perspectives, based on their own experiences. Recently declared a week off fro everybody between xmas and new years. Bristol Myers Squibb to Participate in the 39th Annual J.P. Morgan Healthcare Conference testtest test. Bristol Myers Squibb Vacation & Paid Time Off 344 employees reported this benefit 4.4 54 Ratings Available to US-based employees Change location Employer Verified Mar 7, 2022 Employee Comments Showing 1-10 of 54 Jan 28, 2023 4.0 Current Direcror in nullnull Comparable to big Pharma company Helpful Report Dec 22, 2022 4.0 Learn more! Insights for Success: We are committed to creating an inclusive environment and have invested in training for woman and underrepresented groups. ,,M|L7^`kBQv# |88960\epmPZyC?r= ,L*P}``rN 0000043468 00000 n I am ready to take up a new challenge and I would like to take this opportunity to put the knowledge and skills acquired during my career at the service of my new employer and future colleagues. 0000193438 00000 n Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. The companys performance in the first quarter of 2021 Furthermore, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right (CVR) remained unaccomplished due to the pending FDA approval as of Dec. 31, 2020. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will Shares of Bristol Myers Squibb Co. BMY, -0.22% sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX, Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Bristol-Myers Squibb bulls will hope to hear the company announce they've not only beaten. We claim: 1. Our financial strength, dedicated workforce and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation and position the company for sustained growth., $ amounts in millions, except per share amounts. Mirati Therapeutics MRTX reported a loss of $3.51 per share for fourth-quarter 2022, narrower than the Zacks . All of our employees must comply with the highest standards of data privacy protection consistent with the laws of the jurisdiction in which they operate. The website may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. There will be a conference call on February 4, 2022 at 8 a.m. hb```b``{Ab,GU\r``8e/Gu sMJM ;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! 0000001396 00000 n Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. I had the opportunity to share insights on our Bristol Myers Squibb . Drug Discovery and Translational Medicine, Equal Employment Opportunity / Disability Assistance. 3 floating holidays. Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. <> **Included as part of the new product portfolio At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. %PDF-1.5 % System. Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). Jewish Calendar 2021 Tuusula, Uusimaa, Finland. Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley LLP is serving as legal counsel. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Wednesday, April 28th. Aug 2010 - Present12 years 8 months. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. , M@C(c{H?X8 G ,Lv9 A00Lbd`d: p` Leixlip, Kildare. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The basis for our security efforts is to protect our employees, operations and intellectual property. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. Our Continuing Business, which represents in-line products and new product portfolio, is expected to grow in the low-double digits and contribute approximately $36.5 billion in 2022. During a conference call at 9 a.m. Shares of Bristol Myers Squibb Co. BMY, +0.36% shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that BMY AGEN. Up to 100% of qualifying tuition costs may be covered, based upon manager discretion and budget. Required to work every rotating weekends, some holidays, and during adverse weather conditions in support of . "Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade." Giovanni Caforio Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. June 08, 2022 06:59 AM Eastern Daylight Time. We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. 0000011978 00000 n Toggle Dropdown. On Nov. 12, 2021, the Commission announced that it has approved certain modifications to Bristol Meyers Squibb's divestiture agreements. 0000012578 00000 n Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. General and technical inquiries. . 0000007229 00000 n We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. "The first of the new aircraft will enter service in late-2023, with the bulk to . Your response will be removed from the review this cannot be undone.